GMX Reliance Gen.

TIDMGMX

RNS Number : 8502D

Reliance GeneMedix PLC

30 March 2011

Reliance GeneMedix plc

(the "Company")

(AIM: GMX)

Reliance GeneMedix plc, the AIM listed biopharmaceutical company, hereby provides an update to the news it released in its interim results announcement on 16 December 2010 that it had submitted an application to the European Medicine Agency ("EMA") for the authority to market its core product, Erythropoietin ("EPO"), in Europe. Based on its initial assessment of the application, EMA has asked for additional data to be provided by the Company which is expected to take more time than permitted by the EMA prescribed schedule.

As a consequence, the Company has decided to withdraw its application to EMA for the time being and is evaluating EMA's comments before developing a plan to generate that data by doing certain additional studies and to resubmit the application in due course.

In accordance with AIM Rule 26, a copy of this announcement is available on the Company's website at www.genemedix.com.

30 March 2011

ENQUIRIES:

Reliance GeneMedix plc Tel: +353 57 932 3572

Vinay Ranade, Chief Executive Officer

Deloitte Corporate Finance Tel: +44 (0)20 7936 3000

Jonathan Hinton, John Ball

Lothbury Financial Services Limited Tel: +44 (0)20 7868 2567

Michael Padley

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUKRVRANAOUAR

Reliance Genemedix (LSE:GMX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Reliance Genemedix (LSE:GMX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024